Acquired hemophagocytic lymphohistiocytosis associated with malignant disease
MONDO:00155442 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug targets deadly immune overreaction in rare disease
Disease control Recruiting nowThis study tests a new drug, ELA026, for people with secondary hemophagocytic lymphohistiocytosis (sHLH), a rare and life-threatening condition where the immune system becomes dangerously overactive. The drug aims to calm this overreaction by removing certain immune cells. The tr…
Phase: PHASE2, PHASE3 • Sponsor: Electra Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail aims to tame deadly immune storm in lymphoma
Disease control Recruiting nowThis study tests a combination of two drugs, zanubrutinib and rituximab, for people with B-cell lymphoma who develop a severe immune overreaction called hemophagocytic lymphohistiocytosis (HLH). The trial will enroll 40 participants and aims to see how well the treatment controls…
Phase: PHASE4 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC